Skip to main content

Cellectar Biosciences, Inc.

corporate_fare Company Profile

Cellectar Biosciences, Inc.

CLRB·NASDAQ·Life Sciences·CIK 0001279704

The company is a late-stage clinical biopharmaceutical company focused on discovering, developing, and commercializing cancer treatments. Its main goal is to use its proprietary phospholipid ether drug conjugate (PDC) delivery platform to create PDCs designed to specifically target cancer cells, aiming for improved effectiveness and better safety due to fewer unintended side effects. The company believes its PDC platform can lead to the next generation of cancer-targeting treatments and plans to develop PDCs both independently and through research and development collaborations. The company primarily focuses on developing its radioconjugate PDC programs, also known as phospholipid radioconjugates (PRCs). These PRCs are designed to deliver a radioisotope directly to cancer cells while limiting exposure to healthy cells. The company believes this characteristic distinguishes its PRCs from many traditional on-market treatments and radiotherapeutics. Its three main programs are: * **CLR 121125 (CLR 125)**: An iodine-125 Auger-emitting program, prepared to enter a clinical trial in 2025. CLR 125, an Auger-emitting PRC, uses iodine-125 as its radiation source and has shown tolerability with minimal toxicities in animal models. * **CLR 121225 (CLR 225)**: An actinium-225 based program. * **iopofosine I 131 (iopofosine)**: A beta-emitting iodine-131 based program that has been extensively studied. On June 4, 2025, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for iopofosine I 131 as a radioconjugate monotherapy for treating relapsed/refractory Waldenstrom macroglobulinemia (r/r WM). On October 6, 2025, the company announced that the European Medicines Agency (EMA) advised that filing for a Conditional Marketing Authorization (CMA) for iopofosine I 131 as a treatment for post-Bruton Tyrosine Kinase inhibitor (BTKi) refractory patients with Waldenstrom macroglobulinemia (WM) could be acceptable for a CMA.

Cellectar Biosciences, Inc. (NASDAQ:CLRB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for CLRB at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for CLRB spans 10-Q, 8-K, 424B3, DEF 14A.

Recent high-impact activity:

  • Cellectar Posts 46c Per-Share Q3 Loss as Cash Runway Tightens
  • Cellectar Q3 Loss Widens to $8.0M; Going Concern Reaffirmed With Runway to Q2 2027
  • Cellectar's Iopofosine Shows 79.2% Major Response in BTKi-Refractory WM, Phase 3 and NDA Planned
  • Cellectar Advances Iopofosine Toward Mid-2027 NDA, Reports Q2 Loss and $34M Cash
  • Cellectar Advances Iopofosine Toward Mid-2027 NDA, Reports Q2 Loss of $6.9M

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$21.79M
Diluted EPS
-$8.35
Op. Cash Flow
-$23.12M
Free Cash Flow
-$23.12M
Operating Income
-$22.98M
Cash & Equivalents
$13.2M
Debt / Equity
0.00×
Shares Outstanding
4.24M sh
Source: 10-K · filed 2026-04-30 · accession 0001104659-26-053090

Short Interest & Short Volume

1.65 days to cover

FINRA reported short interest of 218,774 shares in CLRB as of the October 30, 2026 settlement, a 17.0% decrease from the prior period — about 1.6 days to cover at its recent average daily volume. On November 20, 2026, 47.3% of CLRB volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)218,774 shares as of October 30, 2026
Change vs prior period▼ 17.0%
Days to cover1.65 at avg daily volume of 132,705
Daily short volume (FINRA facilities)47.3% of 55,179 shares on November 20, 2026
5-day average short volume42.6%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for CLRB, detected from its recent SEC filings · based on capital-structure filings through 2026-06-02.

1 shelf registration

Resale Registration Finalized · Origin of Shares

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with C →
$0.79 -0.88% today
52-week range · as of 2026-11-10 $0.79 – $4.7
Market cap
$8M
Volume
81.1K (0.6× avg)
3-mo avg 140.2K
Live data · 2026-11-22 12:37 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CLRB - Latest Insights

CLRB
Nov 10, 2026, 7:15 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $1.30
Real-time Price: $0.790 info
Change: -$0.510 (-39%) info
Market Cap: $8.001M info
CLRB
Nov 10, 2026, 6:55 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.28
Real-time Price: $0.790 info
Change: -$0.490 (-38%) info
Market Cap: $8.001M info
CLRB
Sep 29, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.80
Real-time Price: $0.790 info
Change: -$1.01 (-56%) info
Market Cap: $8.001M info
CLRB
Aug 13, 2026, 7:25 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.60
Real-time Price: $0.790 info
Change: -$1.81 (-70%) info
Market Cap: $8.001M info
CLRB
Aug 13, 2026, 7:15 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.60
Real-time Price: $0.790 info
Change: -$1.81 (-70%) info
Market Cap: $8.001M info
CLRB
Aug 13, 2026, 7:00 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.60
Real-time Price: $0.790 info
Change: -$1.81 (-70%) info
Market Cap: $8.001M info
CLRB
Jul 10, 2026, 5:13 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.82
Real-time Price: $0.790 info
Change: -$2.03 (-72%) info
Market Cap: $8.001M info
CLRB
Jun 02, 2026, 6:01 AM EDT
Filing Type: 424B3
Importance Score:
8
Price at Filing: $2.89
Real-time Price: $0.790 info
Change: -$2.10 (-73%) info
Market Cap: $8.001M info
CLRB
May 28, 2026, 5:13 PM EDT
Filing Type: DEF 14A
Importance Score:
9
Price at Filing: $3.14
Real-time Price: $0.790 info
Change: -$2.35 (-75%) info
Market Cap: $8.001M info
CLRB
May 19, 2026, 5:05 PM EDT
Filing Type: S-1
Importance Score:
8
Price at Filing: $3.04
Real-time Price: $0.790 info
Change: -$2.25 (-74%) info
Market Cap: $8.001M info
CLRB
May 18, 2026, 5:00 PM EDT
Filing Type: PRE 14A
Importance Score:
9
Price at Filing: $3.16
Real-time Price: $0.790 info
Change: -$2.37 (-75%) info
Market Cap: $8.001M info
CLRB
May 18, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.14
Real-time Price: $0.790 info
Change: -$2.35 (-75%) info
Market Cap: $8.001M info
CLRB
May 14, 2026, 7:23 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $2.90
Real-time Price: $0.790 info
Change: -$2.11 (-73%) info
Market Cap: $8.001M info
CLRB
May 14, 2026, 7:00 AM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $2.92
Real-time Price: $0.790 info
Change: -$2.13 (-73%) info
Market Cap: $8.001M info
CLRB
May 11, 2026, 8:07 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $2.92
Real-time Price: $0.790 info
Change: -$2.13 (-73%) info
Market Cap: $8.001M info
CLRB
May 08, 2026, 6:04 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $3.36
Real-time Price: $0.790 info
Change: -$2.57 (-76%) info
Market Cap: $8.001M info
CLRB
May 06, 2026, 11:48 AM EDT
Filing Type: 424B5
Importance Score:
9
Price at Filing: $3.30
Real-time Price: $0.790 info
Change: -$2.51 (-76%) info
Market Cap: $8.001M info
CLRB
May 05, 2026, 7:10 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $6.15
Real-time Price: $0.790 info
Change: -$5.36 (-87%) info
Market Cap: $8.001M info
CLRB
Apr 21, 2026, 10:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $2.99
Real-time Price: $0.790 info
Change: -$2.20 (-74%) info
Market Cap: $8.001M info
CLRB
Apr 14, 2026, 8:35 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.70
Real-time Price: $0.790 info
Change: -$1.91 (-71%) info
Market Cap: $8.001M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets